---
title: Overview
description: Peptides for weight loss and metabolic health
---

## Overview

Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide. Each of these peptides offers unique mechanisms of action and significant benefits for weight loss and metabolic health.

## Tirzepatide

- **Mechanism**: Dual GIP/GLP-1 receptor agonist
- **Key Benefits**:
  - Significant weight loss
  - Improved glycemic control
  - Enhanced insulin sensitivity
  - Cardiovascular health benefits
- **Dosage**: Once-weekly injection, 2.5 mg to 15 mg

## Retatrutide

- **Mechanism**: Triple-agonist targeting GIP, GLP-1, and glucagon receptors
- **Key Benefits**:
  - Substantial weight loss
  - Improved glycemic control
  - Enhanced metabolic function
  - Potential liver health benefits
- **Dosage**: Once-weekly injection, doses explored from 1 mg to 12 mg

## Cagrilintide

- **Mechanism**: Long-acting amylin receptor agonist
- **Key Benefits**:
  - Significant weight loss
  - Enhanced satiety
  - Improved glycemic control
  - Potential cardiovascular benefits
- **Dosage**: Once-weekly injection, doses explored from 0.3 mg to 4.5 mg

## Common Benefits

All three peptides offer:
1. Substantial weight loss
2. Improved metabolic health
3. Enhanced quality of life
4. Potential long-term health benefits
5. Convenient once-weekly administration

## Conclusion

Tirzepatide, retatrutide, and cagrilintide represent a new frontier in the treatment of obesity and type 2 diabetes. With their unique mechanisms and impressive efficacy profiles, these peptide therapies offer hope for improved outcomes in patients struggling with weight management and metabolic disorders.
